Assay of Lymphokine-Activated Killer Activity Generated From Bone Marrow Cells of Children With Acute Lymphoblastic Leukemia

• Published in: Blood 1990-01, Vol.75 (1), p.160-165
• Main Authors: Zhou, Muxiang, Findley, Harry W., Davis, Rogena, Ragab, Abdelsalam H.
• Format: Article
• Language: English
• Subjects: Adolescent; Antigens, CD - analysis; Antineoplastic agents; Biological and medical sciences; Bone Marrow - immunology; Bone Marrow - pathology; Chemotherapy; Cytotoxicity, Immunologic; HLA-DR Antigens - analysis; Humans; Immunity, Cellular; In Vitro Techniques; Interleukin-2 - pharmacology; Interleukin-4 - pharmacology; Killer Cells, Lymphokine-Activated - immunology; Medical sciences; Pharmacology. Drug treatments; Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology; Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V75.1.160.160

We recently reported that low molecular weight B-cell growth factor (LMW-BCGF) plus recombinant interleukin-2 (rIL-2) synergistically induced lymphokine-activated killer (LAK) activity from the bone marrow (BM) cells of children with acute lymphoblastic leukemia (ALL). The kinetics of cell growth, antigenic phenotype, and lytic activity of the generated effector cells were further analyzed in this study. BM cells from ALL patients with active disease and in complete remission (CR) were cultured with a combination of LMW-BCGF and rIL-2. Monoclonal antibodies (anti-CD3 and anti-Leu 19) and immunomagnetic beads were used to separate LAK cells into three subsets: CD3 + /Leu 19-, CD3 + /Leu 19 +, and CD3-/Leu 19+. Cytotoxicity assays with different subsets were performed versus K562, Raji, and autologous leukemic cells, using a 3-hour 51Cr release test. There was a significant cell expansion of 54-fold (mean value) for CD3+ cells and 15-fold for Leu 19+ cells in culture with LMW-BCGF plus rIL-2 for 7 to 14 days, whereas no cell expansion was observed in culture with rIL-2 alone. Although NK activity (K562) was generated from leukemic BM cells in culture with rIL-2 alone, it is only about one third of that generated in culture with rIL-2 plus LMW-BCGF. Analysis of lytic activity of cells generated in the latter cultures demonstrated that CD3 — /Leu 19+ cells expressed highest lytic activity against NK-sensitive K562 cells as well as against NK-resistant Raji cells. CD3+/Leu 19+ cells showed median cytotoxicity, and CD3+ /Leu 19— cells mediated only minimal cytotoxic activity. Also, lytic activity of CD3— /Leu 19+ cells against autologous leukemic blasts was noted in patients with active disease. Our results demonstrate that LAK activity generated from BM cells by LMW-BCGF and r-IL2 is mediated mainly by two types of Leu 19+ cells: CD3 — / Leu 19 + NK cells and CD3 + / Leu 19 + T cells. Although CD3 + T cells (both Leu 19+ and Leu 19—) mediated less anti-tumor cytotoxicity than CD3— /Leu 19+ cells, the former cells were the major expanding cell population in culture with LMW-BCGF and rIL-2. The new culture system may be effective in generation of cells with LAK activity for therapeutic use.